Nasacort, Flonase Competition Heats Up As Sanofi Appeals NAD Review
This article was originally published in The Tan Sheet
Executive Summary
Chattem appeals a National Advertising Division decision from a review of advertising comparing its Nasacort nasal allergy spray to GSK’s Flonase. The Sanofi business maintains NAD relied on a “cookbook” approach to determine whether claims for the product are substantiated.
You may also be interested in...
Children's Flonase Is Latest Play For Nasal Allergy Spray Market Share
Children's Flonase, like Children's Nasacort, is the same formulation and is indicated for the same overall age groups as the original product, but its labeling includes additional detail for use by children.
Children's Flonase Is Latest Play For Nasal Allergy Spray Market Share
Children's Flonase, like Children's Nasacort, is the same formulation and is indicated for the same overall age groups as the original product, but its labeling includes additional detail for use by children.
Clarion Brands Argues NAD Turns Deaf Ear To Tinnitus Claims Review
Clarion Brands appeals NAD’s recommendations to discontinue a testimonial and other claims that convey the message its Lipo-Flavonoid Plus substantially reduces or eliminates tinnitus and the symptoms of Ménière’s disease.